HUMACYTE INC. - COMMON STOCK

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

28 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

08 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

04 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

26 Sep 2024 16:26:25 By Nasdaq GlobeNewswire

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in September

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Second Quarter 2024 Financial Results and Business Update

13 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

31 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

17 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in May

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte First Quarter 2024 Financial Results and Business Update

10 May 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

06 May 2024 07:00:00 By Nasdaq GlobeNewswire